These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22294638)

  • 1. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study.
    Saleem B; Brown AK; Quinn M; Karim Z; Hensor EM; Conaghan P; Peterfy C; Wakefield RJ; Emery P
    Ann Rheum Dis; 2012 Aug; 71(8):1316-21. PubMed ID: 22294638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.
    Bechman K; Tweehuysen L; Garrood T; Scott DL; Cope AP; Galloway JB; Ma MHY
    J Rheumatol; 2018 Nov; 45(11):1515-1521. PubMed ID: 30173149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
    Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
    Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
    Ahmad HA; Baker JF; Conaghan PG; Emery P; Huizinga TWJ; Elbez Y; Banerjee S; Østergaard M
    Arthritis Res Ther; 2022 Feb; 24(1):47. PubMed ID: 35172859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study.
    Baker KF; Skelton AJ; Lendrem DW; Scadeng A; Thompson B; Pratt AG; Isaacs JD
    J Autoimmun; 2019 Dec; 105():102298. PubMed ID: 31280933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission.
    van der Ven M; Kuijper TM; Gerards AH; Tchetverikov I; Weel AE; van Zeben J; Hazes JM; Luime JJ
    Rheumatology (Oxford); 2017 Aug; 56(8):1276-1281. PubMed ID: 28407127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.
    Brown AK; Quinn MA; Karim Z; Conaghan PG; Peterfy CG; Hensor E; Wakefield RJ; O'Connor PJ; Emery P
    Arthritis Rheum; 2006 Dec; 54(12):3761-73. PubMed ID: 17133543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
    Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
    Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
    Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
    Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.